Nanovibronix (NASDAQ:FEED – Get Free Report) is one of 27 publicly-traded companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it compare to its competitors? We will compare Nanovibronix to similar companies based on the strength of its risk, earnings, institutional ownership, valuation, dividends, analyst recommendations and profitability.
Analyst Ratings
This is a breakdown of recent recommendations for Nanovibronix and its competitors, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nanovibronix | 1 | 0 | 0 | 0 | 1.00 |
| Nanovibronix Competitors | 80 | 82 | 161 | 7 | 2.29 |
As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 55.05%. Given Nanovibronix’s competitors stronger consensus rating and higher probable upside, analysts plainly believe Nanovibronix has less favorable growth aspects than its competitors.
Insider and Institutional Ownership
Profitability
This table compares Nanovibronix and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nanovibronix | -275.12% | -24.78% | -19.24% |
| Nanovibronix Competitors | -569.68% | -122.96% | -53.63% |
Valuation & Earnings
This table compares Nanovibronix and its competitors top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Nanovibronix | $2.56 million | -$3.70 million | -0.05 |
| Nanovibronix Competitors | $61.19 million | -$32.64 million | 5.16 |
Nanovibronix’s competitors have higher revenue, but lower earnings than Nanovibronix. Nanovibronix is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Volatility and Risk
Nanovibronix has a beta of 2.26, indicating that its stock price is 126% more volatile than the S&P 500. Comparatively, Nanovibronix’s competitors have a beta of 1.80, indicating that their average stock price is 80% more volatile than the S&P 500.
Summary
Nanovibronix competitors beat Nanovibronix on 8 of the 13 factors compared.
Nanovibronix Company Profile
NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.
Receive News & Ratings for Nanovibronix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nanovibronix and related companies with MarketBeat.com's FREE daily email newsletter.
